EXACT DETAILS SURROUNDING CARMAT NEWS BLACKOUT UNCLEAR

Artificial Heart Trials Continue, Media's Position Uncertain

As a follow up to a piece we wrote on renewed clinical trials by Carmat in July 2014, it has come to light that the French company has implemented a news blackout regarding any new implantations of its artificial heart. The embargo is in response to the media scrum that occurred around the announcement of the first implantation and subsequent death 74 days later of Claude Dany. According to a Carmat press release from September 8, 2014, “The Company would like to remind readers that, in accordance with good clinical practice and subject to regulatory obligations or specific circumstances, it is not planning to publish any information on the interim results of this ongoing feasibility study.”

The situation regarding the news blackout is not exactly clear as the Wall Street Journal carried an article dated September 8, 2014 claiming Carmat had implanted a second patient with its pioneering artificial heart. We will keep our readers updated on the situation as it develops.